Navigation Links
Actinium Pharmaceuticals to Host Corporate Update and Virtual Roadshow Conference Call on November 11
Date:10/31/2013

NEW YORK, Oct. 31, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing  innovative targeted payload immunotherapeutics for the treatment of advanced cancers, will host a general corporate update and Virtual Roadshow to discuss the current plans for Iomab™-B at 11:00 AM EDT on November 11, 2013.

The company will discuss the outcome of the recent end of phase two FDA meeting and also the next steps for its Iomab™-B product candidate which is being readied for a pivotal trial.  Iomab™-B has completed several physician sponsored clinical trials examining its potential as a bone marrow conditioning regimen for hematopoietic stem cell transplantation (HSCT) in various blood cancers including a phase I/II study (study 1432) in relapsed and/or refractory elderly acute myeloid leukemia (AML) patients.  The results of study 1432 demonstrated the potential of Iomab™-B to create a new treatment paradigm for HSCT by: expanding the pool to ineligible patients who do not have any viable treatment options currently; enabling a shorter and safer preparatory interval for HCST; reducing post-transplant complications; and showing a clear survival benefit including curative potential.  

Webcast / Telecast Information:

Date: Tuesday, November 11, 2013

Time: 11:00 AM EDT

US Dial-in (Toll-free): 1-877-705-6003

International Dial-in: 1-201-493-6725

For the live and archived webcast, please visit the Investors page on the Actinium website at www.actiniumpharmaceuticals.com or https://viavid.webcasts.com/starthere.jsp?ei=1025173

A replay of the call will be available through December 11, 2013. To access the replay, please call 1-877-870-5176 if calling from '/>"/>

SOURCE Actinium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Actinium Pharmaceuticals Inc. Pays Regulatory Milestone to Abbott Biotherapeutics Corp.
2. Actinium Pharmaceuticals Announces The Addition of The Fred Hutchinson Cancer Research Center To Actiniums Multicenter Clinical Trial For Patients With Acute Myeloid Leukemia
3. Actinium Pharmaceuticals and Philogen S.p.A. Announce Collaboration for Alpha Therapy Based Antiangiogenesis Program
4. Actinium Pharmaceuticals Strengthens Management Team
5. Actinium Pharmaceuticals Stockholders Vote to Approve Fundraising and Public Listing
6. Actinium Pharmaceuticals Commences Screening for the Second Cohort of Patients in the Companys Ongoing Phase I/II Trial in Acute Myeloid Leukemia
7. Gerri Henwood Joins Actinium Pharmaceuticals as Chief Development Officer
8. Actinium Pharmaceuticals Announces New Round of Financing
9. Actinium Pharmaceuticals Sponsors Webinar on Clinical Use of Alpha Immunotherapy
10. Additional Clinical Data from Two Trials on Actinium Pharmaceuticals Iomab-B to be Presented at American Society of Hematology (ASH) Annual Meeting
11. University of Pennsylvania joins Actinium Pharmaceuticals Multicenter Actimab-A Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... BUENA, N.J., July 24, 2014  IGI Laboratories, Inc. (NYSE ... and manufacturing company, announced its financial results for the second ... Highlights , Total revenues of $6.5 million in ... the same quarter in 2013 , Total revenues of ... an increase of 78% over the same period in 2013 ...
(Date:7/24/2014)... , July 24, 2014  Alimera Sciences, Inc. ... that specializes in the research, development and commercialization of ... its second quarter of fiscal year 2014 financial results ... An investor conference call will follow on the same ... conference call will be hosted by Dan Myers ...
(Date:7/24/2014)...  Kinex Pharmaceuticals announced the receipt of an allowance ... for the commencement of a Phase I clinical study ... to be allowed by the US FDA in the ... orally active and highly selective inhibitor of Src tyrosine ... of p53, G2/M arrest of proliferating cell populations and ...
Breaking Medicine Technology:IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7Alimera Sciences To Release Second Quarter 2014 Results 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 4
... 5 Diplomat Specialty Pharmacy,announced today that their ... is now live and being utilized to manage,their ... eNAV(TM) as a,disease management tool for all disease ... Crohn,s Disease,and Chronic Kidney Disease., "Our current ...
... of Insulin Doses Administered Were Delivered Within Pre-Determined ... Guidelines and Standard Dosing Limitations, ... the dose accuracy of the SoloSTAR(R) disposable insulin pen,prefilled ... glulisine [rDNA origin] injection), found the pens,accurately delivered all ...
Cached Medicine Technology:Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System 2New Study Confirms Dose-Accuracy of SoloSTAR(R) Prefilled Insulin Pen 2
(Date:7/25/2014)... Agoura Hills dentist , Dr. Amir Choroomi, is ... is one of the most powerful whitening treatments available today, ... light-assisted treatment uses a prescription-strength gel that can penetrate quickly ... up stains that are in both the enamel and the ... and tobacco stains. , About Dr. Amir Choroomi, Expert ...
(Date:7/25/2014)... Health Advocate™, Inc., the nation’s leading ... West Corporation, is introducing its newest solution in an ... Enhance Quality. , The webinar will be held twice ... again at 2 PM ET. For more information or ... or call 866.799.2655. , In an environment of ...
(Date:7/25/2014)... quickly after Manchester research , Clinical judgement, combined ... arrival, is effective in reducing unnecessary hospital admissions ... findings of a research group in Manchester, published ... a huge difference to a large number of ... for emergency hospital admission. In Manchester, the incidence ...
(Date:7/25/2014)... prevents obesity could be on the horizon. Bacteria ... inhibit weight gain, insulin resistance and other adverse ... University investigators have discovered. , "Of course it,s ... senior investigator Sean Davies, Ph.D., assistant professor of ... negative consequences of obesity in mice, even though ...
(Date:7/25/2014)... York, New York (PRWEB) July 25, 2014 ... JDRF’s revenue and spending during fiscal year 2013 (July 1, ... National Institutes of Health (NIH), the JDRF is the largest ... It has global reach and relationships with most of ... positioned to deliver a cure for type 1 diabetes in ...
Breaking Medicine News(10 mins):Health News:Agoura Hills Dentist, Dr. Amir Choroomi, is Now Offering a Promotion on Zoom Whitening 2Health News:Health Advocate™, Inc., Holds Webinar to Introduce Provider-Centered Analytics 2Health News:Health Advocate™, Inc., Holds Webinar to Introduce Provider-Centered Analytics 3Health News:Heart attack patients could be treated more quickly after Manchester research 2Health News:Vanderbilt study examines bacteria's ability to fight obesity 2Health News:Report: JDRF 2013 Annual Research Spending Down by $50 million 2
... to GSVM medical college in Kanpur remained affected today ... elite educational institutions entered the 11th day here. // ... the protest against Centre's decision to implement 27 per ... representatives of agitating doctors said., ,However, sources at ...
... a good way of relieving stress and providing the mind ... that exercise can lift a person's spirits// , and there ... clinical depression. Exercise helps in the reduction of anger, fatigue ... walking or running has become popular among health freaks. It ...
... some researchers found that milk chocolate containing caffeine has ... having better reaction times. ,Hence, chocolate ... others. ,Adding value to the above study, ... Professer, Dr. Bryan Raudenbush, Wheeling Jesuit University has done ...
... regulate breathing abnormalities of premature babies. Artificial breathing equipments ... with caffeine therapy and found to have a lower incidence ... , ,About 2,000 premature babies, who weighed below 1,250 grams, ... were studied. , ,More than 47 per ...
... direct talks with Prime Minister Manmohan Singh and decided to ... meeting with the medicos during which he told them that ... which would see a huge growth in the educational opportunities ... Prime Minister assured the medicos that they need not be ...
... A research conducted by the King’s Collage London, analysed health reports ... war in 2003 with those who took part// in the 1991 ... ,The study findings that are published in The Lancet ... War Syndrome" in British male armed forces personnel deployed to the ...
Cached Medicine News:
... non-adhesive sealing method maintains the ... (HALS) procedures, allowing the surgeon ... throughout. Because HALS requires incisions ... patients experience less trauma compared ...
... series offers a range of standard, ... design delivers therapy to meet the ... results in commercial and clinical effectiveness ... in the SleepStyle 200 series is ...
... The SleepStyle 200 series offers ... integrated CPAP models. The design delivers ... patients. Performance features promote results in ... care. The strongest differentiator in the ...
... series offers a range of standard, ... design delivers therapy to meet the ... results in commercial and clinical effectiveness ... in the SleepStyle 200 series is ...
Medicine Products: